June is Myasthenia Gravis (MG) Awareness Month. The treatment landscape for MG has changed quickly. Patients with generalized MG now have targeted treatment options that were limited or unavailable just a few years ago.
But access to new medications has not always kept pace with innovation. Patient support program (PSP) managers now face an important question. Is the infrastructure for specialty medication access ready to support patients diagnosed with MG, including those starting new-to-market therapies?
In many cases, the answer is no.
Most patient support programs are built on the idea that a newly diagnosed patient is ready and able to complete an enrollment process. But for patients who have spent years searching for answers before receiving a rare disease diagnosis, that idea may not reflect their reality.
Patient drop-off is the point in the specialty medication journey where a patient stops moving forward before successfully starting or refilling their therapy. In rare disease states like MG, drop-offs frequently occur due to administrative friction, physical fatigue, or lengthy delays during critical transition points like prior authorization (PA) approval, hub enrollment, and the first fill.
Even when patients are highly motivated, barriers like physical exhaustion, emotional burnout, and other access barriers can make a simple enrollment process feel overwhelming.
That can be especially true for patients diagnosed with MG. Research consistently links MG with symptoms like unpredictable muscle weakness and fatigue, or difficulties with speaking, chewing, swallowing, or vision. A patient may leave a clinic visit motivated to start therapy but lose steam later that day.
Patient support program teams can help close this gap with support that doesn’t wait for patients to call in. A provider-to-patient text message, delivered moments after a prescription is sent to the pharmacy, can encourage patients to start and stay on therapy.
"Proactive outreach" has become a common phrase in PSP managers’ strategies. But for those facing specialty medication barriers, like patients diagnosed with MG, it’s worth being specific about what support should look like.
Being proactive does not mean reaching out more often. It means reaching patients with relevant information that helps them take the next step before confusion, fatigue, cost concerns, or delays get in the way.
Outreach triggered at the point of prescribing can reach patients when they are most prepared to engage. Waiting until after insurance verification, hub enrollment, or another downstream step may create avoidable delays.
For a patient managing the fluctuating symptoms of MG, every moment matters.
Well-timed messages can help keep momentum going from the start. They give patients a clear path forward while the conversation with their physician is still fresh and when support can be most effective.
Text messages can be a meaningful way to support patients managing muscle weakness, fatigue, issues with vision, or difficulty speaking.
A text message that connects patients to therapy-specific guidance, savings information, enrollment instructions, refill reminders, or other support resources proactively helps patients without asking them to search for answers on their own.
For patients managing rare or complex diseases, the channel matters because the burden of follow-through is already high. Support should reduce effort, not add another task.
Outreach works best when it breaks the medication journey into clear, manageable steps. That may include helping patients understand prior authorization, complete hub enrollment, review financial support options, or stay on track after therapy begins.
The goal is to help more patients connect with the right support earlier and with less friction.
Starting therapy is only one part of the journey. Patients may continue to face access, affordability, adherence, and refill barriers after the prescription is written.
Proactive support should continue at key moments when patients are most likely to need help. That might include guidance when starting a self-injectable or refill reminders. These touchpoints can help patients feel less alone and help PSP teams identify when patients may need more support.
Early, automated patient engagement can help reduce gaps between prescribing, enrollment, pharmacy coordination, and starting therapy. It also gives commercial teams a more consistent way to support patients on the path to better health outcomes.
MG Awareness month is a useful time to look at how well you support patients diagnosed with rare or complex diseases. That means looking beyond overall enrollment rates and focusing on the points where patients fall out of the journey.
Where are patients losing momentum? At first contact? After enrollment, but before prior authorization approval? After approval, but before the first fill? After the first fill, but before refill?
Each exit point may reflect a different gap in the program. A patient who never responds to initial outreach may need support sooner, through a more accessible channel. Someone who is waiting for prior authorization approval may need clearer guidance on what to expect. And a patient who doesn’t move forward from approval to first fill may be facing cost concerns, confusion about why they can’t get it from their preferred pharmacy, or fatigue that makes follow-through difficult.
Treating these distinct moments as one broad “engagement” problem can lead teams to ignore the importance of improving the patient experience.
Start your audit with two simple questions: What is the patient being asked to do at each step, and how easy is it for them to do it? A program that depends on patients to answer phone calls, find forms, remember next steps, or call back during business hours may create barriers unintentionally.
Avoid letting delays turn into drop-offs. See how Timely helps support patient outreach for rare and complex therapies.